Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.
As the Canadian economy faces a contraction in GDP and potential easing from the Bank of Canada, investors are increasingly looking towards dividend stocks as a reliable income source amidst shifting market dynamics. In this environment, selecting dividend stocks with strong fundamentals and stable cash flows can offer resilience and consistent returns, making them an attractive option for those navigating the current economic landscape.
American Express just made waves with a major partnership announcement, becoming the official payments partner at Hard Rock Stadium, the Miami Dolphins, and the Formula 1 Miami Grand Prix. This multi-year deal brings exclusive fan perks to eligible cardholders, from presale event tickets to dedicated lounges and entrances. For investors, this is not just marketing; it represents another step in Amex’s expansion of its global sports and entertainment footprint, aimed squarely at deepening...
CGI (TSX:GIB.A) has just secured a 10-year deal with the State of New Jersey to continue supporting its disaster recovery system, along with a multi-year contract to overhaul Texas’ statewide enterprise financial platform. Both announcements reinforce CGI’s U.S. public sector momentum and signal that the company is strengthening its footprint in mission-critical projects with long-term revenue streams. For investors, this kind of contract pipeline not only boosts confidence in future cash...
Pfizer (PFE) just landed a significant regulatory win. On August 27, the company and its partner BioNTech announced that the U.S. Food and Drug Administration approved their updated LP.8.1-adapted monovalent COVID-19 vaccine. This new version is cleared for adults aged 65 and over, as well as younger high-risk individuals, thanks to clinical data showing it provides stronger immune protection against multiple newer COVID strains. For investors wondering where this leaves Pfizer as COVID...
If you own shares of AbbVie or have been watching from the sidelines, the latest wave of clinical trial results may have just put the stock back on your radar. AbbVie has made headlines with positive updates across a handful of key programs, including encouraging data from its pivotal Phase 3 trial of upadacitinib (RINVOQ) in severe alopecia areata as well as early-stage progress in multiple cancer therapies. These developments, paired with upwardly revised earnings estimates, are fueling a...
